GB9403250D0 - Therapeutic use of myelin-associated glycoprotein (mag) - Google Patents

Therapeutic use of myelin-associated glycoprotein (mag)

Info

Publication number: GB9403250D0
Authority: GB; United Kingdom
Prior art keywords: myelin; mag; therapeutic use; associated glycoprotein; glycoprotein
Prior art date: 1994-02-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

GB9403250A

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

McGill University

Original Assignee

McGill University

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-02-21

Filing date

1994-02-21

Publication date

1994-04-13

1994-02-21 Application filed by McGill University filed Critical McGill University

1994-02-21 Priority to GB9403250A priority Critical patent/GB9403250D0/en

1994-04-13 Publication of GB9403250D0 publication Critical patent/GB9403250D0/en

1995-02-17 Priority to AU17035/95A priority patent/AU1703595A/en

1995-02-17 Priority to CA 2183630 priority patent/CA2183630A1/en

1995-02-17 Priority to PCT/CA1995/000089 priority patent/WO1995022344A1/en

1997-08-21 Priority to SE9703032A priority patent/SE9703032D0/en

Status Pending legal-status Critical Current

Priority Applications (5)

Application Number	Priority Date	Filing Date	Title
GB9403250A GB9403250D0 (en)	1994-02-21	1994-02-21	Therapeutic use of myelin-associated glycoprotein (mag)
AU17035/95A AU1703595A (en)	1994-02-21	1995-02-17	Therapeutic use of myelin-associated glycoprotein (mag)
CA 2183630 CA2183630A1 (en)	1994-02-21	1995-02-17	Therapeutic use of myelin-associated glycoprotein (mag)
PCT/CA1995/000089 WO1995022344A1 (en)	1994-02-21	1995-02-17	Therapeutic use of myelin-associated glycoprotein (mag)
SE9703032A SE9703032D0 (en)	1994-02-21	1997-08-21	Therapeutic use of myelin-associated glycoportein

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB9403250A GB9403250D0 (en)	1994-02-21	1994-02-21	Therapeutic use of myelin-associated glycoprotein (mag)

Publications (1)

Publication Number	Publication Date
GB9403250D0 true GB9403250D0 (en)	1994-04-13

Family

ID=10750657

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
GB9403250A Pending GB9403250D0 (en)	1994-02-21	1994-02-21	Therapeutic use of myelin-associated glycoprotein (mag)

Country Status (5)

Country	Link
AU (1)	AU1703595A (en)
CA (1)	CA2183630A1 (en)
GB (1)	GB9403250D0 (en)
SE (1)	SE9703032D0 (en)
WO (1)	WO1995022344A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5932542A (en)	1995-06-27	1999-08-03	Research Foundation Of Cuny, Hunter College	Composition and methods using myelin-associated glycoprotein (MAG) and inhibitors thereof
CA2190418A1 (en) *	1996-11-15	1998-05-15	Zhi-Cheng Xiao	Neuron and neural tumor growth regulatory system, antibodies thereto and uses thereof
WO1999053945A1 (en) *	1998-04-16	1999-10-28	Samuel David	Neuron growth inhibitory molecules or derivatives thereof used to immunize mammals thereby promoting axon regeneration
US20020072493A1 (en)	1998-05-19	2002-06-13	Yeda Research And Development Co. Ltd.	Activated T cells, nervous system-specific antigens and their uses
WO1999060021A2 (en) *	1998-05-19	1999-11-25	Yeda Research And Development Co. Ltd.	Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system
US6632429B1 (en)	1999-12-17	2003-10-14	Joan M. Fallon	Methods for treating pervasive development disorders
US20070053895A1 (en)	2000-08-14	2007-03-08	Fallon Joan M	Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
WO2002014537A2 (en) *	2000-08-14	2002-02-21	Fallon Joan M	Methods for diagnosing and treating dysautonomia and other dysautonomic conditions
US8030002B2 (en)	2000-11-16	2011-10-04	Curemark Llc	Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
GB0103174D0 (en) *	2001-02-08	2001-03-28	Smithkline Beecham Plc	Novel method of treatment
TWI323265B (en)	2002-08-06	2010-04-11	Glaxo Group Ltd	Antibodies
GB0306309D0 (en) *	2003-03-19	2003-04-23	Glaxo Group Ltd	Method of treatment
US20080058282A1 (en)	2005-08-30	2008-03-06	Fallon Joan M	Use of lactulose in the treatment of autism
GB0525662D0 (en)	2005-12-16	2006-01-25	Glaxo Group Ltd	Immunoglobulins
US8658163B2 (en)	2008-03-13	2014-02-25	Curemark Llc	Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en)	2008-04-18	2011-12-27	Curemark Llc	Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en)	2008-06-26	2016-04-26	Curemark Llc	Methods and compositions for the treatment of symptoms of Williams Syndrome
US11016104B2 (en)	2008-07-01	2021-05-25	Curemark, Llc	Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US10776453B2 (en)	2008-08-04	2020-09-15	Galenagen, Llc	Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en)	2008-10-03	2010-04-15	Fallon Joan M	Methods and compositions for the treatment of symptoms of prion diseases
ES2727746T3 (en)	2009-01-06	2019-10-18	Galenagen Llc	Oral compositions for the treatment or prevention of E. coli infections
ES2578618T3 (en)	2009-01-06	2016-07-28	Curelon Llc	Compositions comprising protease, amylase and lipase for use in the treatment of Staphylococcus aureus infections
US9056050B2 (en)	2009-04-13	2015-06-16	Curemark Llc	Enzyme delivery systems and methods of preparation and use
US9511125B2 (en)	2009-10-21	2016-12-06	Curemark Llc	Methods and compositions for the treatment of influenza
US8974782B2 (en)	2011-02-07	2015-03-10	Glaxo Group Limited	Treatment of stroke comprising anti-MAG antibodies
MX347770B (en)	2011-04-21	2017-05-12	Curemark Llc	Compounds for the treatment of neuropsychiatric disorders.
US10350278B2 (en)	2012-05-30	2019-07-16	Curemark, Llc	Methods of treating Celiac disease
AU2018250823A1 (en)	2017-04-10	2019-10-17	Curemark, Llc	Compositions for treating addiction
US11541009B2 (en)	2020-09-10	2023-01-03	Curemark, Llc	Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SU1721092A1 (en) *	1990-02-26	1992-03-23	Институт Цитологии Ан Ссср	Strain of hydride cultured mammalian cells mus musculus l - a producer of monoclonal antibody to brain myelin glycoproteine, inhibiting activity of natural human killers

1994
- 1994-02-21 GB GB9403250A patent/GB9403250D0/en active Pending
1995
- 1995-02-17 WO PCT/CA1995/000089 patent/WO1995022344A1/en active Application Filing
- 1995-02-17 CA CA 2183630 patent/CA2183630A1/en not_active Abandoned
- 1995-02-17 AU AU17035/95A patent/AU1703595A/en not_active Abandoned
1997
- 1997-08-21 SE SE9703032A patent/SE9703032D0/en unknown

Also Published As

Publication number	Publication date
AU1703595A (en)	1995-09-04
CA2183630A1 (en)	1995-08-24
WO1995022344A1 (en)	1995-08-24
SE9703032D0 (en)	1997-08-21

Publication	Publication Date	Title
GB9403250D0 (en)	1994-04-13	Therapeutic use of myelin-associated glycoprotein (mag)
GB9423910D0 (en)	1995-01-11	Therapeutic agents
GB9417956D0 (en)	1994-10-26	Therapeutic agents
GB9415996D0 (en)	1994-09-28	Therapeutic agents
GB9418545D0 (en)	1994-11-02	Therapeutic agents
GB9415997D0 (en)	1994-09-28	Therapeutic agents
GB9417310D0 (en)	1994-10-19	Therapeutic agents
GB9416189D0 (en)	1994-09-28	Therapeutic agents
GB9416162D0 (en)	1994-09-28	Therapeutic agents
GB9402641D0 (en)	1994-04-06	Therapeutic agents
GB9410031D0 (en)	1994-07-06	Therapeutic agents
GB9423460D0 (en)	1995-01-11	Therapeutic agents
GB9423682D0 (en)	1995-01-11	Therapeutic agents
GB9415575D0 (en)	1994-09-21	Therapeutic agents
GB9401879D0 (en)	1994-03-30	Therapeutic agents
GB9409264D0 (en)	1994-06-29	Therapeutic agents
ZA951420B (en)	1995-08-25	Therapeutic agents
GB9402011D0 (en)	1994-03-30	Therapeutic agents
GB9411953D0 (en)	1994-08-03	Therapeutic agents
GB9401642D0 (en)	1994-03-23	Therapeutic agents
GB9414334D0 (en)	1994-09-07	Therapeutic agents
GB9411954D0 (en)	1994-08-03	Therapeutic agents
GB9415553D0 (en)	1994-09-21	Therapeutic agents
GB9410080D0 (en)	1994-07-06	Therapeutic agents
GB9410074D0 (en)	1994-07-06	Therapeutic agents